



Funding Non-Invasive Prenatal Screening for Fetal Aneuploidy

APPLICABILITY

This document applies to all healthcare providers who are requesting funding for non-invasive prenatal screening for fetal aneuploidy through the Genetic Resource Centre (GRC).

PURPOSE

This guideline provides information regarding when the GRC will fund non-invasive prenatal screening for fetal aneuploidy.

GUIDELINE

In this document, non-invasive prenatal screening refers to prenatal screening tests that analyze cell-free DNA in maternal blood.

The GRC is only able to fund non-invasive prenatal screening for fetal aneuploidy when ALL of the following conditions are met:

- 1) There is an increased risk for fetal aneuploidy in an ongoing pregnancy, and the patient would normally be offered an invasive diagnostic procedure.
- 2) **Either**
 - A) There is an increased risk for fetal health complications associated with an invasive procedure
 - a. Maternal HIV
 - b. Maternal hepatitis
 - OR**
 - B) The risk for miscarriage/preterm delivery and/or maternal health complications associated with the procedure is greater than the average population risk
 - a. Abnormally invasive placentation
 - b. Shortened cervix < 25 mm < 24 weeks gestation or cerclage in situ
 - OR**
 - C) Performing an invasive procedure is technically challenging
 - a. At least two failed attempts at chorionic villus sampling and/or amniocentesis

RESPONSIBILITY

Ordering healthcare providers and the Genetic Resource Centre personnel are responsible for implementing this guideline.

CONTACT INFORMATION

Genetic Resource Centre (phone: 403-955-5400; email: grc@albertaprecisionlabs.ca; fax: 403-592-4238)